We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics

77 hedge funds and large institutions have $50.2M invested in Lineage Cell Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,600% more call options, than puts

Call options by funds: $67K | Put options by funds: $1K

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

1.44% less ownership

Funds ownership: 37.18% → 35.74% (-1.4%)

18% less funds holding

Funds holding: 94 → 77 (-17)

48% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 25

66% less capital inflows, than outflows

Capital inflows: $967K | Capital outflows: $2.8M

89% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 19

Holders
77
Holders Change
-17
Holders Change %
-18.09%
% of All Funds
1.55%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
2
Increased
13
Reduced
25
Closed
19
Calls
$67​K
Puts
$1​K
Net Calls
+$66​K
Net Calls Change
-⁠$30​K

LCTX Hedge Fund Activity: Q3 2020 in Review

77 of the 4,971 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2020, worth a combined $50.2M — up 3.6% from $48.5M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of LCTX and 2 opened new positions — a net loss of 17 holders — while 25 trimmed existing stakes and 13 added.

The largest buyer was Defender Capital, adding an estimated $356K. The largest seller was Jane Street, cutting an estimated $718K.

  • 77 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2020, down from 94 in Q2 2020.
  • Funds reported $50.2M of Lineage Cell Therapeutics stock for Q3 2020, up 3.6% quarter-over-quarter.
  • 2 funds opened new Lineage Cell Therapeutics positions in Q3 2020 and 19 closed out, a net change of -17 holders.
  • The largest Lineage Cell Therapeutics buyer in Q3 2020 was Defender Capital, an estimated $356K added.
  • The largest Lineage Cell Therapeutics seller in Q3 2020 was Jane Street, an estimated $718K sold.

Based on aggregated 13F filings for Q3 2020.